TRCT
GRTX

Tower Research Capital (TRC)’s Galera Therapeutics, Inc. Common Stock GRTX Stock Holding History

Tower Research Capital (TRC)’s Portfolio GRTX Stock Details GRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-17,323
Closed -$44K – 6459
2023
Q1 		$44K Sell
17,323
-496
-3% -$1.02K ﹤0.01% 2624
2022
Q4 		$27K Buy
17,819
+7,587
+74% +$12.3K ﹤0.01% 2857
2022
Q3 		$18K Buy
+10,232
New +$14.5K ﹤0.01% 4039
2022
Q2 		– Sell
-1,316
Closed -$3K – 6689
2022
Q1 		$3K Buy
+1,316
New +$3.43K ﹤0.01% 5447
2021
Q4 		– Sell
-2,276
Closed -$19K – 6706
2021
Q3 		$19K Buy
2,276
+2,057
+939% +$17.6K ﹤0.01% 3783
2021
Q2 		$2K Sell
219
-1,653
-88% -$13.4K ﹤0.01% 5095
2021
Q1 		$17K Buy
1,872
+126
+7% +$1.38K ﹤0.01% 4024
2020
Q4 		$18K Sell
1,746
-6,732
-79% -$73.6K ﹤0.01% 3946
2020
Q3 		$77K Buy
8,478
+7,063
+499% +$55.9K ﹤0.01% 3334
2020
Q2 		$10K Buy
1,415
+1,315
+1,315% +$14K ﹤0.01% 4027
2020
Q1 		$1K Sell
100
-2,020
-95% -$26K ﹤0.01% 2879
2019
Q4 		$28K Buy
+2,120
New +$25.9K ﹤0.01% 1719

Other funds holding GRTX

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Tower Research Capital (TRC)'s GRTX Position: Q2 2023 in Review

Tower Research Capital (TRC) sold out of Galera Therapeutics, Inc. Common Stock (GRTX) in Q2 2023, closing a stake of 17,323 shares — an estimated $44K sold.

Tower Research Capital (TRC) first reported a position in GRTX in Q4 2019 and held it in 12 quarters. The position peaked at $77K in Q3 2020. 55 funds tracked by Wall St. Rank hold GRTX as of Q2 2023.

  • Tower Research Capital (TRC) reported no remaining Galera Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 17,323 Galera Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $44K.
  • Tower Research Capital (TRC) first reported a position in Galera Therapeutics, Inc. Common Stock in Q4 2019 and held it in 12 quarters.
  • Tower Research Capital (TRC)'s Galera Therapeutics, Inc. Common Stock position peaked at $77K in Q3 2020.
  • 55 funds tracked by Wall St. Rank held Galera Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2023, filed 14 Aug 2023.